SCPH vs. OPTN, CMRX, CHMA, FBIO, AQST, OLMA, YMAB, PEPG, IGMS, and CYRX
Should you be buying scPharmaceuticals stock or one of its competitors? The main competitors of scPharmaceuticals include OptiNose (OPTN), Chimerix (CMRX), Chiasma (CHMA), Fortress Biotech (FBIO), Aquestive Therapeutics (AQST), Olema Pharmaceuticals (OLMA), Y-mAbs Therapeutics (YMAB), PepGen (PEPG), IGM Biosciences (IGMS), and Cryoport (CYRX).
scPharmaceuticals (NASDAQ:SCPH) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.
OptiNose has a net margin of -41.55% compared to scPharmaceuticals' net margin of -327.29%. OptiNose's return on equity of 0.00% beat scPharmaceuticals' return on equity.
OptiNose has higher revenue and earnings than scPharmaceuticals. OptiNose is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks.
scPharmaceuticals has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500. Comparatively, OptiNose has a beta of -0.1, indicating that its share price is 110% less volatile than the S&P 500.
OptiNose received 88 more outperform votes than scPharmaceuticals when rated by MarketBeat users. However, 66.24% of users gave scPharmaceuticals an outperform vote while only 63.31% of users gave OptiNose an outperform vote.
scPharmaceuticals currently has a consensus target price of $19.00, indicating a potential upside of 385.93%. OptiNose has a consensus target price of $3.67, indicating a potential upside of 239.51%. Given scPharmaceuticals' higher possible upside, equities analysts clearly believe scPharmaceuticals is more favorable than OptiNose.
In the previous week, scPharmaceuticals and scPharmaceuticals both had 3 articles in the media. scPharmaceuticals' average media sentiment score of 0.85 beat OptiNose's score of 0.85 indicating that scPharmaceuticals is being referred to more favorably in the media.
89.5% of scPharmaceuticals shares are owned by institutional investors. Comparatively, 85.6% of OptiNose shares are owned by institutional investors. 5.5% of scPharmaceuticals shares are owned by company insiders. Comparatively, 2.7% of OptiNose shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
scPharmaceuticals and OptiNose tied by winning 8 of the 16 factors compared between the two stocks.
Get scPharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
scPharmaceuticals Competitors List
Related Companies and Tools
